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OBJECTIVES The study was done to determine the effects of propranolol, enalaprilat, verapamil, and
caffeine on the vasodilatory properties of the adenosine A2A-receptor agonist ATL-146e
(ATL).
BACKGROUND ATL is a new adenosine A2A-receptor agonist proposed as a vasodilator for myocardial stress
perfusion imaging. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and
calcium blockers are commonly used for the treatment of coronary artery disease (CAD), and
their effect on ATL-mediated vasodilation is unknown. Dietary intake of caffeine is also
common.
METHODS In 19 anesthetized, open-chest dogs, hemodynamic responses to bolus injections of ATL
(1.0 g/kg) and adenosine (60 g/kg) were recorded before and after administration of
propranolol (1.0 mg/kg, ATL only), enalaprilat (0.3 mg/kg, ATL only), caffeine (5.0 mg/kg,
ATL only), and verapamil (0.2 mg/kg bolus, ATL and adenosine).
RESULTS Neither propranolol nor enalaprilat attenuated the ATL-mediated vasodilation (225  86%
and 237  67% increase, respectively, p  NS vs. control). Caffeine had an inhibitory effect
(97  28% increase, p  0.05 vs. control). Verapamil blunted both ATL- and adenosine-
induced vasodilation (63  20% and 35  7%, respectively, p  0.05 vs. baseline), and also
inhibited the vasodilation induced by the adenosine triphosphate-sensitive potassium (KATP)
channel activator pinacidil.
CONCLUSIONS Beta-blockers and ACE inhibitors do not reduce the maximal coronary flow response to
adenosine A2A-agonists, whereas verapamil attenuated this vasodilation through inhibition of
KATP channels. The inhibitory effect of verapamil and KATP channel inhibitors like
glybenclamide on pharmacologic stress using adenosine or adenosine A2A-receptor agonists
should be evaluated in the clinical setting to determine their potential for reducing the
sensitivity of CAD detection with perfusion imaging. (J Am Coll Cardiol 2002;40:
1687–94) © 2002 by the American College of Cardiology Foundation
Pharmacologic stress using adenosine or dipyridamole is an
alternative to exercise stress for the detection of coronary
artery disease (CAD) with myocardial perfusion imaging.
However, the frequent occurrence of undesirable side effects
such as chest pain, headache, dyspnea, and atrioventricular
conduction abnormalities (1–3) has stimulated the develop-
ment of highly selective adenosine A2A-receptor agonists
(4 – 6). These compounds induce an A2A-receptor–
mediated coronary vasodilation without stimulation of the
adenosine A1-, A2B-, and A3-receptors, thereby potentially
eliminating the side effects. Recently, a new class of stable
and highly potent and selective adenosine A2A-receptor ago-
nists has been synthesized at the University of Virginia (7).
Among them, the compound ATL-146e has shown promise
as a vasodilator for myocardial perfusion imaging (8).
Beta-adrenergic receptor blockers, angiotensin-converting
enzyme (ACE) inhibitors, and calcium blockers are benefi-
cial in the treatment of CAD and are commonly prescribed
(9–11). Additionally, dietary intake of caffeinated food or
beverages is also common and has been shown to alter the
pharmacological vasodilation induced by dipyridamole (12)
due to the nonselective adenosine receptor antagonist prop-
erty of caffeine (13). The kinetics of the ATL-146e–induced
vasodilation in the absence of other pharmacologic agents
have been previously characterized in detail (8). In the
present study, we sought to investigate any pharmacological
interactions between the hemodynamic effects of ATL-146e
and a beta-adrenergic blocker (propranalol), an ACE inhib-
itor (enalaprilat), a calcium channel blocker (verapamil), and
caffeine. Before ATL-146e can be introduced for clinical
imaging, the influence of these commonly used drugs in
patients with cardiovascular disease requires examination.
METHODS
Surgical preparation. Nineteen fasted, adult mongrel dogs
(20.9  0.7 kg, range 16.8 to 28.2 kg) were anesthetized
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with sodium pentobarbital (30 mg/kg IV), tracheally intu-
bated, and mechanically ventilated. Open-chest surgery and
instrumentation were performed as previously described (8).
Experimental protocols. PROTOCOL 1: EFFECTS OF PRO-
PRANOLOL, ENALAPRILAT, VERAPAMIL, AND CAFFEINE ON
HEMODYNAMIC RESPONSES TO VASODILATORS. After
baseline measurements, hemodynamic responses to boluses
of adenosine (60 g/kg), ATL-146e (1.0 g/kg), and a
second adenosine A2A-receptor agonist, CGS-21680 (2.0
g/kg), were monitored. The effect of IV bolus injections of
propranolol (1.0 mg/kg), enalaprilat (0.3 mg/kg), verapamil
(0.2 mg/kg), and caffeine (5.0 mg/kg) on ATL-146e hemo-
dynamic responses were monitored 10 min after each drug
injection when hemodynamics had reached a steady state.
Drug injection order was randomized, except for caffeine,
which was always injected last because of its known nonse-
lective inhibition of adenosine receptors (13). The effect of
verapamil on hemodynamic responses to adenosine and
CGS-21680 was also studied.
PROTOCOL 2: EFFECT OF INCREASING VERAPAMIL DOSES
ON THE HEMODYNAMIC RESPONSES TO ADENOSINE
AND ATL-146E. The hemodynamic responses to bolus in-
jections of adenosine and ATL-146e were recorded in
the absence or presence of varying infusion rates of vera-
pamil (0.002, 0.004, and 0.02 mg/kg/min IV). In one dog,
blood sampling was performed for determination of
plasma verapamil concentration at each infusion rate. In two
dogs, the effect of a 0.02 mg/kg/min infusion rate on the
increase in regional myocardial blood flow mediated by an
IV adenosine infusion (250 g/kg/min) was determined
with radioactive microspheres after placement of a critical
stenosis on the left anterior descending coronary artery
(LAD). A critical stenosis was defined as the point at
which baseline flow was unchanged but the reactive hyper-
emic response to a brief LAD occlusion was completely
abolished. The dose of adenosine used has been shown
to produce maximal coronary vasodilation in our canine
model (8).
PROTOCOL 3: MECHANISM FOR THE VERAPAMIL-MEDIATED
INHIBITION OF ADENOSINE AND ATL VASODILATOR AC-
TION.
(a) Effect of pressure drop reversal: after baseline record-
ings, hemodynamic responses to boluses of adenosine
and ATL-146e were recorded. An IV infusion of
verapamil (0.02 mg/kg/min) was started, and adenosine
and ATL-146e responses were again recorded. An IV
calcium infusion (3.0 mg/kg/min) was then begun and
maintained until reversal of the verapamil-induced de-
crease in mean arterial pressure (MAP) was observed.
Adenosine and ATL-146e hemodynamic responses
were then recorded.
(b) Role of adenosine triphosphate-dependent potassium
(KATP) channels: the hemodynamic response to an
adenosine bolus was recorded before and after IV
administration of the KATP channel inhibitor glyben-
clamide (0.3 mg/kg), and the hemodynamic responses
to intracoronary infusions of the KATP channel activator
pinacidil (1.0 g/kg/min) were recorded in the absence
or presence of verapamil (0.02 mg/kg/min IV).
Quantification of regional myocardial blood flow with
radioactive microspheres. After euthanasia, hearts were
removed and sliced into four rings from apex to base. Each
slice was divided into six transmural sections, which were
subdivided into epicardial, midwall, and endocardial seg-
ments. The resulting 72 myocardial tissue samples were
counted for microspheres in a gamma-well scintillation
counter (MINAXI 5500, PerkinElmer Life Sciences Inc.,
Downer’s Grove, Illinois). The window settings on the gamma
counter were Sn-113, 340 to 440 keV; Sr-85, 450 to 580 keV;
Nb-95, 640 to 840 keV; and Sc-46, 842 to 1300 keV.
Plasma verapamil. In one dog in Protocol 2, 2 ml of
arterial blood was withdrawn at baseline and during each
verapamil infusion and centrifuged (1,900 rpm  10 min at
4°C) for the assessment of plasma verapamil concentration
(National Medical Service, Willow Grove, Pennsylvania).
Data analysis. When expressed in the text as a mean
percent increase, coronary vasodilation was quantified as the
ratio of peak ultrasonic LAD flow observed after vasodilator
injection to baseline flow observed immediately prior to the
vasodilator injection in each animal and the results averaged.
Statistical analysis. Results are presented as mean 
SEM. Computations were performed with SYSTAT soft-
ware (SPSS Inc., Chicago, Illinois). Comparisons were
performed using one-way analysis of variance and repeated-
measures analysis of variance. When appropriate, post hoc
testing was performed using the Bonferroni tests. The
p values  0.05 were considered statistically significant.
RESULTS
Protocol 1: effects of propranolol, enalaprilat, verapamil,
and caffeine on hemodynamic responses to vasodilators.
Results are shown in Table 1. At baseline, LAD flow
increased by an average of 249  44% following ATL-146e
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CFR  coronary flow reserve
dP/dt  peak positive first derivative of left ventricular
pressure with respect to time
HR  heart rate
IV  intravenous
KATP  adenosine triphosphate-sensitive potassium
LAD  left anterior descending coronary artery
LAP  left atrial pressure
LCx  left circumflex coronary artery
MAP  mean arterial pressure
NO  nitric oxide
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bolus injection (p  0.05 vs. baseline). ATL-146e induced
a slight decrease in MAP (p  0.05 vs. baseline) and a
significant increase in both heart rate (HR) and peak
positive first derivative of left ventricular pressure with
respect to time (dP/dt) (p  0.05 vs. baseline). Left atrial
pressure (LAP) was not affected by the adenosine A2A-
receptor agonist.
Propranolol (1.0 mg/kg) significantly decreased resting
LAD flow, MAP, HR, and dP/dt, and had no effect on
LAP. In the presence of propranolol, ATL-146e induced a
mean 225  86% increase in LAD flow (p  NS vs.
control) without decreasing MAP. The increases in HR and
dP/dt observed with ATL-146e alone at baseline were
abolished.
Enalaprilat (0.3 mg/kg) had no effect on resting LAD
flow, dP/dt, and LAP. The MAP was significantly de-
creased and HR was slightly but significantly increased by
the ACE inhibitor. In the presence of enalaprilat, ATL-
146e induced a mean 237  67% increase in LAD flow
(p  NS vs. control) and significantly decreased MAP and
increased dP/dt. However, enalaprilat abolished the increase
in HR observed with ATL-146e alone at baseline.
Caffeine (5.0 mg/kg) had no effect on resting LAD flow,
dP/dt, and LAP. A trend toward an increase in MAP,
which did not reach statistical significance (p  0.069), was
observed, as was a small but significant increase in HR (p 
0.05). As expected, the increase in LAD flow with ATL-
146e was attenuated in the presence of caffeine (97  28%,
p  0.05 vs. control). ATL-146e produced no changes in
MAP, HR, and LAP.
Verapamil (0.2 mg/kg) increased LAD resting flow by an
average 46  15% (p  0.05), and significantly decreased
MAP and HR. As expected, dP/dt decreased in response to
the calcium blocker (p  0.058). Unexpectedly, in the
presence of verapamil, the increases in LAD flow produced
by the adenosine A2A-receptor agonists ATL-146e and
CGS-21680 were markedly blunted (63  20% and 67 
8% increase, respectively; p  0.05 vs. control) (Table 2).
The hemodynamic responses to a bolus injection of aden-
osine in the absence and presence of verapamil are also
presented in Table 2. As was observed with the adenosine
A2A-receptor agonists, the mean 149  34% increase in
LAD flow produced by adenosine in the absence of vera-
pamil was blunted at 35  7% (p  0.05 vs. control) in the
presence of this calcium channel blocker.
Protocol 2: effect of increasing verapamil doses on the
hemodynamic responses to vasodilators. Analysis of
plasma verapamil concentration in one dog revealed a linear
relationship between the verapamil dose and its plasma
concentration (r2  0.99, p  0.001). Infusion rates of
0.002, 0.004, and 0.02 mg/kg/min resulted in verapamil
plasma concentrations of 22, 46, and 230 ng/ml, respec-
tively. Hemodynamic data are presented in Table 3 and
Figures 1 and 2. As the verapamil infusion rate increased,
baseline coronary flow tended to increase, and resting MAP
progressively decreased (p  0.01 vs. baseline at the highest
verapamil infusion rate).
Coronary flow responses to adenosine and ATL-146e in
the absence or presence of increasing doses of verapamil are
depicted in Figures 1A and 1B. Note that with increasing
verapamil infusion rates, a progressive inhibition of the
coronary flow responses to adenosine and ATL-146e was
Table 1. Hemodynamic Responses to ATL-146e Bolus Injections in the Absence or Presence of
Propranolol, Enalaprilat, Verapamil, or Caffeine
LAD Flow
(ml/min)
MAP
(mm Hg)
HR
(beats/min)
dP/dt
(mm Hg/s)
LAP
(mm Hg)
Control (n  7)
Baseline 29.6  7.4 107.0  6.7 125.6  6.0 1,802  129 5.1  0.3
Stress 93.1  15.7* 93.0  6.7* 134.1  5.2* 2,386  217* 5.3  0.4
Propranolol (n  4)
Baseline 30.8  6.8 101.8  7.3 119.8  12.4 1,765  211 5.5  0.6
Drug 27.0  7.7* 87.0  4.3* 103.8  9.3* 1,205  83* 6.3  0.9
Stress 76.5  12.1*† 78.8  3.8* 106.0  9.7 1,302  50‡ 7.8  0.8*†
Enalaprilat (n  4)
Baseline 30.8  10.2 103.5  10.4 110.3  14.9 1,537  150 5.8  0.9
Drug 30.8  9.6 96.3  9.3* 113.0  15.0* 1,715  230 5.5  1.2
Stress 88.0  10.8*† 86.0  9.1*† 118.0  15.3* 1,995  259*† 5.8  1.4
Verapamil (n  7)
Baseline 30.1  7.8 110.6  7.0 120.3  8.9 1,817  177 6.1  0.5
Drug 39.9  7.8* 91.0  8.5* 105.7  9.0* 1,627  203 7.0  0.3
Stress 63.0  12.5*†‡ 89.1  8.4* 108.1  9.3* 1,790  233‡ 7.1  0.3
Caffeine (n  4)
Baseline 24.0  5.7 91.3  5.6 103.3  10.6 1,253  93 6.5  1.2
Drug 22.8  5.5 98.0  7.7 105.0  10.5* 1,281  133 7.3  1.1
Stress 43.3  8.6*†‡ 97.5  7.6 104.3  10.3 1,430  94*‡ 6.3  1.1
ATL-146e bolus dose was 1.0 g/kg. ATL-146e–mediated vasodilation was tested in the absence or presence of propranolol 1.0
mg/kg, enalaprilat 0.3 mg/kg, verapamil 0.2 mg/kg, and caffeine 5.0 mg/kg. Values are expressed as mean  SEM. *p  0.05
vs. baseline. †p  0.05 vs. drug. ‡p  0.05 vs. control stress.
HR  heart rate; dP/dt  peak positive first derivative of left ventricular pressure with respect to time; LAD  ultrasonic left
anterior descending coronary artery; LAP  left atrial pressure; MAP  mean arterial pressure.
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observed. At the highest verapamil dose, peak coronary flow
after ATL-146e or adenosine administration was signifi-
cantly reduced (p  0.05 vs. control), and coronary flow
reserve (CFR) decreased from 4.4  0.8 to 2.0  0.1 with
ATL-146e, and from 3.1 0.1 to 1.8 0.2 with adenosine
(p  0.05). As shown in Table 3, with increasing verapamil
infusion rates there was also a progressive attenuation of the
ATL-induced increases in dP/dt and HR that were com-
pletely abolished by the highest verapamil dose.
Absolute myocardial blood flow disparity. Shown in Fig-
ure 2 are the absolute regional myocardial blood flows
before and during IV administration of adenosine (250
g/kg/min) in the absence and presence of a 0.02 mg/kg/
min IV verapamil infusion. In the absence of verapamil,
adenosine induced a fivefold increase in regional flow in the
left circumflex coronary artery (LCx) zone, from 1.01 
0.01 ml/min/g to 5.05  0.11 ml/min/g (p  0.05),
whereas flow in the LAD zone did not increase owing to the
presence of a critical stenosis. During verapamil infusion,
the increase in flow in the normal LCx zone was only
1.6-fold and did not reach statistical significance. Therefore,
the marked fourfold LCx-to-LAD flow disparity with
adenosine was severely attenuated in the presence of vera-
pamil (1.8-fold, p  0.05).
Protocol 3: mechanism for the verapamil-mediated inhi-
bition of adenosine and ATL-146e vasodilator action.
(a) Effect of pressure drop reversal: to determine whether
the impaired adenosine- or ATL-146e–mediated vaso-
dilation in the presence of verapamil was a nonspecific
consequence of the calcium blocker-mediated decrease
in MAP, we reversed the drop in MAP with an IV
calcium infusion (3.0 mg/kg/min). As shown in Figures
3A and 3B, despite the recovery of MAP with calcium
infusion, the vasodilator action of both adenosine (Fig.
3A) and ATL (Fig. 3B) remained blunted by the
presence of verapamil (0.02 mg/kg/min).
(b) Role of KATP channels: results are presented in Figure
4. The adenosine-mediated increase in flow (211 
49%) was totally abolished by the KATP channel inhib-
itor glybenclamide. Moreover, the vasodilation induced
by an intracoronary infusion of the KATP channel
activator pinacidil (134  10%, p  0.05 vs. baseline)
was severely blunted in the presence of verapamil (22 
19%, p  0.05 vs. pinacidil).
DISCUSSION
The new adenosine A2A-receptor agonist ATL-146e dis-
plays favorable properties for use as a vasodilator for
myocardial stress perfusion imaging after an IV bolus
injection (7,8). We sought to determine whether commonly
used cardiac drugs such as a beta-adrenergic blocker, an
ACE inhibitor, and a calcium blocker interfered with the
pharmacologic effects of this novel A2A-agonist. We also
evaluated the effect of caffeine, a nonselective adenosine
receptor antagonist (13), on the hemodynamic response to a
bolus injection of ATL-146e.
Effects of a beta-blocker, an ACE inhibitor, and caffeine
on hemodynamic responses to ATL-146e. The control
hemodynamic response to a bolus injection of ATL-146e
observed in this study is identical to our previously pub-
lished data (8). The 3.5-fold increase in coronary flow was
accompanied by a slight decrease in MAP and by increases
in both HR and dP/dt. These responses are direct conse-
quences of adenosine A2A-receptor stimulation (14,15).
Effect of a beta-blocker. The dose of propranolol used in
this study (1.0 mg/kg) was previously shown to produce
Table 2. Hemodynamic Responses to Adenosine and CGS-21680 in the Absence or Presence of
Verapamil
LAD Flow
(ml/min)
MAP
(mm Hg)
HR
(beats/min)
dP/dt
(mm Hg/s)
LAP
(mm Hg)
CGS-21680 (n  3)
Control
Baseline 51.7  6.6 115.7  2.0 147.3  20.9 2,081  272 5.7  0.7
Stress 141.0  6.2* 95.0  6.8 158.3  20.4* 2,703  281* 5.0  1.5
Verapamil
Baseline 53.3  9.8 111.0  2.0 140.7  25.7 2,010  210 6.3  0.3
Drug 54.0  7.5 87.7  1.5* 134.0  25.5 1,802  207* 7.0  1.5
Stress 91.3  16.2‡ 81.7  6.1*‡ 137.7  25.2† 1,938  156‡ 8.3  1.2‡
Adenosine (n  4)
Control
Baseline 37.5  12.1 112.8  6.2 130.0  6.7 2,181  192 5.5  0.3
Stress 81.8  19.0* 84.0  10.7* 129.3  7.7 2,317  234 5.0  0.9
Verapamil
Baseline 38.3  12.7 118.8  4.6 125.5  7.3 2,158  70 5.5  0.6
Drug 51.8  11.2* 99.3  7.4* 113.8  8.6* 2,074  182 6.3  0.5
Stress 71.3  16.0*† 83.0  11.2*† 109.0  9.5* 2,076  311 6.0  0.6
CGS-21680 and adenosine bolus doses were 2.0 g/kg and 60 g/kg, respectively. CGS-21680– and adenosine-mediated
vasodilations were tested in the absence or presence of verapamil 0.2 mg/kg. Values are expressed as mean  SEM. *p  0.05
vs. baseline. †p  0.05 vs. drug. ‡p  0.05 vs. control stress.
dP/dt  peak positive first derivative of left ventricular pressure with respect to time; HR  heart rate; LAD  ultrasonic
left anterior descending coronary artery; LAP  left atrial pressure; MAP  mean arterial pressure.
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Table 3. Effect of Increasing Verapamil Infusion Rates on the Hemodynamic Responses to Adenosine and ATL-146e
LAD Flow (ml/min) MAP (mm Hg) HR (beats/min) dP/dt (mm Hg/s) LAP (mm Hg)
ATL-146e Adenosine ATL-146e Adenosine ATL-146e Adenosine ATL-146e Adenosine ATL-146e Adenosine
Control
Baseline 22.5  2.5 24.8  4.6 124.3  10.1 126.5  9.0 116.8  7.7 120.3  6.7 1,664  126 1,773  136 5.5  1.0 6.8  0.9
Stress 103.5  26.0* 78.3  4.6* 105.5  10.1* 94.0  9.2* 146.0  11.0* 119.8  8.3 2,480  137* 1,911  126 4.5  1.0 4.3  0.9
Verapamil 0.002
Baseline 23.5  2.6 24.8  1.5 131.5  6.4 131.5  6.4 118.5  9.8 118.5  9.8 1,742  169 1,742  169 4.8  0.9 4.8  0.9
Drug 28.5  0.9 28.8  0.9 124.8  7.7 127.5  7.8 120.3  11.2 120.3  11.0 1,766  195 1,730  197 5.0  0.7 5.0  1.0
Stress 88.8  20.9* 73.5  2.2*† 109.8  7.5*† 101.0  11.5*† 139.3  11.0*† 124.5  9.9 2,366  141*† 1,895  137* 3.8  0.5 4.3  0.9
Verapamil 0.004
Baseline 23.8  1.3 23.0  1.9 130.3  8.6 130.3  8.6 116.0  11.8 116.0  11.8 1,507  67 1,507  67 5.5  1.0 5.5  1.0
Drug 31.3  2.8* 27.5  4.1 122.0  11.7 120.0  10.0* 115.5  15.0 116.3  13.9 1,485  104 1,483  114 6.0  1.1 5.3  0.9
Stress 88.0  9.3*† 58.8  5.2*† 108.8  7.8* 100.0  13.5*† 128.3  14.6† 120.3  15.0 2,001  126† 1,672  54 5.3  0.9 4.5  0.9
Verapamil 0.02
Baseline 20.5  3.9 20.5  3.9 123.8  6.8 123.8  6.8 105.5  12.8 105.5  12.8 1,322  99 1,322  99 6.5  1.0 6.5  1.0
Drug 30.3  6.6 29.5  5.9 99.0  8.9* 102.8  7.9* 109.3  14.7 110.8  13.8 1,412  269 1,467  257 7.3  1.9 6.5  1.9
Stress 60.3  14.9*† 51.3  10.0*† 95.8  10.7* 93.0  9.9* 111.3  14.0 113.3  13.7 1,579  231‡ 1,550  277 7.0  1.5 6.0  1.3
ATL-146e (ATL) and adenosine bolus doses were 1.0 g/kg and 60.0 g/kg, respectively. ATL-146e– and adenosine-mediated vasodilations were tested in the absence or presence of verapamil 0.002 mg/kg/min (0.002), 0.004 mg/kg/min
(0.004), and 0.02 mg/kg/min (0.02). Values are expressed as mean  SEM of four experiments. *p  0.05 vs. baseline. †p  0.05 vs. drug. ‡p  0.05 vs. control stress.
dP/dt  peak positive first derivative of left ventricular pressure with respect to time; HR  heart rate; LAD  ultrasonic left anterior descending coronary artery; LAP  left atrial pressure; MAP  mean arterial pressure.
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affected by the presence of propranolol. An increase in
maximal coronary flow after adenosine injection has been
observed clinically after administration of metoprolol, a
selective beta1-blocker (17,19), and has been attributed to a
decrease in coronary vascular resistance during hyperemia.
This in turn was attributed to a diminution of extravascular
compressive forces in the presence of the beta1-blocker.
However, Kern et al. (20) have shown that nonselective
beta-blockers such as propranolol could potentiate coronary
vasoconstriction after cold pressor testing in patients with
CAD, leading to a reduced CFR. Such effects on coronary
vascular resistance and CFR were not observed in healthy
volunteers (20), which is consistent with our experimental
data in normal dogs.
Effect of an ACE inhibitor. As shown by others in the
same experimental model (21), the dose of enalaprilat (0.3
mg/kg) used in this study significantly reduced MAP.
Baseline coronary flow was not affected, in accordance with
previously published clinical data (22,23). We observed that
the ATL-146e–mediated increase in coronary flow was not
significantly affected by the presence of enalaprilat. Previous
studies have shown that ACE inhibition may improve
endothelium-dependent vasodilation both in healthy volun-
teers and in patients with atherosclerosis (22,23) through
nitric oxide (NO)-mediated mechanisms. However, poten-
tiation of vasodilation with ACE inhibition only occurs
when the specific tissue affinity of the ACE inhibitor being
used is favorable (24). Because of its low tissue affinity,
Figure 3. Effect of reversing the verapamil (0.02 mg/kg/min)-induced mean arterial pressure (MAP) drop with calcium infusion (3.0 mg/kg/min) on
adenosine (A) and ATL-146e (B) flow responses. Note that the vasodilator action of both adenosine and ATL-146e was not restored despite the recovery
in MAP, indicating that the blunted coronary flow response was not caused by the verapamil-induced drop in pressure. Data are mean  SEM of four
experiments. *p  0.05 vs. control.
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enalaprilat has been shown previously to have no effect on
radial artery vasodilation (24), in accordance with the results
of the present study.
Effect of caffeine. The dose of caffeine used in this study
(5.0 mg/kg) is equivalent to the serum level found in
patients after consumption of two cups of brewed coffee 2 to
3 h before stress (12). As previously reported by Jain et al.
(25) in anesthetized dogs, this dose of caffeine has little
effect on baseline hemodynamic parameters. Caffeine sig-
nificantly decreased ATL-induced vasodilation as a result of
its nonselective antagonist effect on adenosine receptors
(13). The reduction in CFR observed in our study in the
presence of caffeine (from 3.5  0.4 to 2.0  0.3, p  0.05)
was similar to that observed clinically by Bottcher et al. (12)
in 12 healthy volunteers after IV dipyridamole injection.
These observations emphasize the need to screen patients
for caffeine dietary intake prior to performing a stress test,
because the drug could blunt vasodilator stress, thereby
decreasing the sensitivity for detection of a significant
coronary stenosis.
Effect of a calcium blocker. Verapamil bolus administra-
tion had a vasodilatory effect, as shown by an increase in
coronary blood flow and a decrease in MAP, and a negative
chronotropic effect. These effects have previously been
observed in both experimental and clinical studies (26,27).
Verapamil significantly decreased the maximal vasodilatory
response to adenosine and ATL-146e. The increase in flow
following another adenosine A2A-receptor agonist, CGS-
21680, was also blunted by verapamil, indicating that the
effect of the calcium blocker was not limited to a specific
adenosine A2A-receptor agonist like ATL-146e. Although
the attenuation in CFR may in part be due to an increase in
baseline coronary flow after verapamil administration, we
also observed a decrease in peak flow following vasodilation.
As shown in Figures 1A and 1B, the decrease in peak
coronary flow achieved after either adenosine or ATL-146e
injection was dose-dependent. Moreover, assessment of
absolute regional myocardial blood flow with radioactive
microspheres showed that infusion of verapamil signifi-
cantly reduced CFR. The three IV verapamil infusion rates
(0.002, 0.004, and 0.02 mg/kg/min) evaluated in this study
resulted in proportional drug plasma concentrations of 22,
46, and 230 ng/ml, respectively. Clinically, the mean vera-
pamil plasma concentration is 120  20 ng/ml in patients
chronically treated with the drug (28). Therefore, the range
of verapamil concentrations achieved in our study is likely to
be encountered in patients.
Calcium infusion reversed the decrease in MAP induced
by calcium channel inhibition with verapamil. However, the
attenuation in ATL-146e– and adenosine-induced vasodi-
lation remained. Therefore, the attenuation of the coronary
flow response was not a secondary effect of calcium channel
blockade on MAP by verapamil.
Adenosine and adenosine A2A-receptor agonists mediate
vasodilation by stimulation of adenosine receptors on endo-
thelial and smooth muscle cells (29), leading to activation of
KATP channels on these cell types. Subsequent activation of
NO production in endothelial cells and hyperpolarization in
smooth muscle cells lead to vasodilation (30). In our model,
inhibition of KATP channels with glybenclamide totally
inhibited the adenosine-mediated vasodilation. In addition
to inhibiting L-type voltage-dependent calcium channels,
Haworth et al. (31) showed that verapamil also strongly
inhibits KATP channels in vitro. Our results confirm this
finding in vivo, because verapamil inhibited the increase in
flow produced by the KATP channel activator pinacidil.
Study limitations. This study was performed in anesthe-
tized animals. Sodium pentobarbital anesthesia is known to
produce hemodynamic changes such as mild tachycardia
and may also blunt reflex changes in HR and/or contractil-
ity. However, the effects of the drugs tested in our study on
baseline hemodynamics were in accordance with previously
published clinical and experimental data, suggesting that
our model was appropriate for investigating the effects of
these drugs on the vasodilatory properties of adenosine and
adenosine A2A-receptor agonists.
Summary. The vasodilator properties of the adenosine
A2A-receptor agonist ATL are not affected by the presence
of the beta-adrenergic blocker propranolol, or the ACE
inhibitor enalaprilat. As reported previously with dipyrid-
amole, caffeine inhibits the increase in flow induced by an
IV injection of ATL-146e due to its known nonselective
inhibition of adenosine receptors. The important new find-
ing in this study is that the calcium blocker verapamil
inhibits the vasodilation produced by adenosine or adeno-
sine A2A-receptor agonists through inhibition of KATP
channels in vivo. The inhibitory effect of verapamil and
KATP channel inhibitors like glybenclamide on pharmaco-
logic stress using adenosine or adenosine A2A-receptor
agonists should be evaluated in the clinical setting to
determine their potential for reducing the sensitivity of
CAD detection with perfusion imaging.
Figure 4. Attenuation of coronary flow responses to adenosine (n 2) and
the KATP channel activator pinacidil (n  3) by glybenclamide and
verapamil, respectively. *p  0.05 vs. baseline. †p  0.05 vs. pinacidil.
LAD  left anterior descending coronary artery.
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